At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 32 enrolled
Drug / intervention
Gefitinib +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase IIa, Open-Label, Multi-Center, Multi-Cohort, Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (Stage IIIB-IV)
In Brief
A Phase 2 clinical trial evaluating Gefitinib, AZD9291, and 2 other interventions for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (Stage IIIB-IV). Completed, enrolled 32 participants across 10 sites.
Detailed Summary
Primary objective: To assess the efficacy of various sequences of either a small molecule or an IMT (IMT-A) followed by a IMT-B (MEDI4736) .
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsQuintiles, Inc.
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJul 2014
Enrollment StartJul 2014
Primary CompletionJun 2016
TodayJul 2026
First PostedJul 2, 2014
Enrollment StartJul 25, 2014
Primary CompletionJun 11, 2016
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 12 years ago
Interventions
Gefitinibdrug
Gefitinib once daily followed by MEDI4736
AZD9291drug
AZD9291 once daily followed by MEDI4736
Selumetinib+Docetaxeldrug
Selumetinib twice daily + docetaxel, followed by MEDI4736
Tremelimumabdrug
Tremelimumab every 4 weeks followed by MEDI4736